Drug Index

Interferon Gamma

Mechanism :

Interferons are a family of naturally occurring proteins, which have molecular weights ranging from 15,000 to 21,000 daltons. Three major classes of interferons have been identified: alfa, beta, and gamma. Interferon beta-1b, interferon alfa, and interferon gamma have overlapping yet distinct biologic activities.

Indication :

  • Chronic granulomatous disease

Contraindications :

Contraindicated in patients who have hypersensitivity to interferon gamma or known hypersensitivity to closely related interferons. Use with caution in seizure disorders and/or compromised CNS function; pre-existing cardiac disease, e.g. ischemia, congestive heart failure and arrhythmias; severe hepatic or renal impairment. Monitor before and during treatment; hematological tests (including FBC, differential white cell count and platelet count), blood chemistry tests (including renal and liver function tests) and urinalysis.

Dosing :

For Body Surface Area >0.5 m²:
50 microgram per m² given subcutaneously thrice a week.
For Body Surface Area <0.5 m²:
1.5 microgram per m² given subcutaneously thrice a week.

Adverse Effect :

Commonly reported adverse effects are fever, headache, chills, myalgia or fatigue, diarrhea, nausea and vomiting, arthralgia, rashes and injection-site reactions.

Interaction :

Serum pro­tein preparations or immunological preparations (e.g. vaccines): Simultaneous administration should be avoided because of the risk for unex­pected amplified immune response.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely
10-20No data on use in renal impairment. Dose as for normal renal function and monitor renal function closely
<10Use with caution due to risk of accumulation. Monitor renal function closely

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxDialysed. Dose as in GFR<10 mL/ min
CAV/VVHDUnlikely dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

There are no dosage adjustments provided in the manufacturer’s labeling; drug accumulation may occur in patients with advanced hepatic disease. If severe transaminase elevations occur during treatment, interrupt and reduce the dose upon resolution.
02/28/2022 04:39:25 Interferon Gamma
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0